新的LFA-1抑制剂Orientin降低了血管新生素II诱导的血管改造
Yitong Wang1, Ying Zhang2, Xiangbo An3
1Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China, No.49 Huayuanbei Road, Beijing, 100191, China; Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Dalian, China.
European journal of pharmacology
|February 24, 2025
概括
奥里丁通过向淋巴细胞功能相关抗原1 (LFA1) 来抑制 ангиотензинII诱导的高血压和血管重塑. 这项研究揭示了Orientin作为心血管疾病的潜在治疗方法.
科学领域:
- 心血管研究研究心血管研究
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 单细胞-内皮细胞相互作用驱动炎症和血管重塑.
- 淋巴细胞功能相关抗原1 (LFA1) 是炎症期间白细胞粘附的关键.
- 对于LFA1和Orientin在 ангиотензинII (Ang II) 诱导的高血压中的作用尚不清楚.
研究的目的:
- 研究LFA1在Ang II诱导的高血压和血管改造中的作用.
- 为了确定Orientin是否可以减轻Ang II诱导的血管变化.
- 探索Orientin作为高血压和血管损伤的潜在治疗剂.
主要方法:
- 在小鼠中输注 ангиотензин II (Ang II),以诱导高血压.
- 血压监测,病理染色,免疫光,免疫组织化学和实时PCR.
- 在体外测试以评估巨细胞迁移和DNA损伤.
主要成果:
- 阻断LFA1和Orientin治疗改善了Ang II诱导的高血压,炎症,纤维化和氧化应激.
- 中和LFA1抗体减少了Ang II触发的巨细胞向内皮细胞的迁移.
- 东方药证明与LFA-1相互作用,并抑制Ang II诱导的血管改造.
结论:
- 东方药作为LFA-1的小分子抑制剂,表现出抗血管重塑性质.
- 东方显示出对血管损伤和高血压的临床治疗有希望.
- 这些发现为心血管疾病提供了新的治疗策略.
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
469
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
469
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
371
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
371
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
455
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
455
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
571
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
571
01:27Open Angle Glaucoma: Treatment
384
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
384
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
401
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
401